BMRN250117P57500
- 0.22
- -0.13-37.14%
Biomarin Pharmaceutical Newsroom
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
Worst Performing Stocks for Tax Loss Selling – Wolfe
BioMarin Pharmaceutical Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
11 Compounder Opportunities According to Goldman: AMD, BDX, INFA
BofA Securities Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $101
J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
Biomarin Pharmaceutical To Present At Evercore ISI HealthCONx Conference; Webcast At 10:00 AM ET
RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
Despite Delivering Investors Losses of 26% Over the Past 1 Year, BioMarin Pharmaceutical (NASDAQ:BMRN) Has Been Growing Its Earnings
Express News | Biomarin Pharmaceutical Inc : RBC Cuts Target Price to $70 From $80
Here's Why BioMarin Pharmaceutical (BMRN) Is a Strong Value Stock
Jefferies Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $122
Jefferies Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now
Biomarin Pharmaceutical To Present At Jefferies London Healthcare Conference; Webcast At 4:00 AM ET
Reported Saturday, BioMarin Presents Real-World Data On VOXZOGO Efficacy And Safety In Children With Achondroplasia At ESPE 2024
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical